A Phase 4 interventional study of Online Lifestyle Behavioral Therapy and Phentermine Hydrochloride 8 MG in Obesity, Obesity; Drug and Lifestyle, Healthy, sponsored by Wake Forest University Health Sciences. Completed at 4 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Wake Forest University Health Sciences · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing phentermine in Obesity — 3 open to participants now, 4 under way, none of them phase 3. Phentermine · Obesity.
Among the 26 studies testing phentermine in Obesity, this one is the 3rd largest by enrollment, is one of 2 that started in 2022, is one of 13 in phase 4, and was the 21st registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →3 of the 26 studies testing phentermine in Obesity are open now, in 1 country. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–65
University of California, Irvine · Sites in United States
Ages 18–70
University of California, San Diego · Sites in United States
Ages 18–80
By country, each count listing its studies:
Phentermine: first FDA approval 1959 (IONAMIN). What it is approved for, and how studies give it, is on its page →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 4 · Phase 4 13
First in 2006; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 870 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 134 across the 26 interventional studies. Of the 21 that completed or were terminated, 16 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 26 have an industry lead sponsor. The 10 most frequent:
Wake Forest University Health Sciences is the lead sponsor of 1,353 studies on the registry; 199 are open to participants now.
Of its 332 completed or terminated interventional studies of FDA-regulated products, 251 (76%) have results posted.
46 studies in Obesity by Wake Forest University Health Sciences: 4 open now, 5 under way, 2 of them phase 3. Of 40 finished, 16 (40%) have results posted.
Among the 46 studies in Obesity by Wake Forest University Health Sciences, this one is the 2nd largest by enrollment of the 40 interventional ones that give a count, is the only one that started in 2022, is one of 3 in phase 4, and was the 39th registered.
Wake Forest University Health Sciences’s Obesity studies by the year they started, since 1997.
2 of the studies testing phentermine in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06854614The Cleveland ClinicSequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial) | 2027-04-28 |
| NCT05975580University of California, IrvinePharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery | 2027-07-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 26 studies testing phentermine in Obesity, from their registry updates:
Among Wake Forest University Health Sciences’s 46 in Obesity:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to understand the long-term effects of the drug phentermine on weight, blood pressure, other health outcomes, and safety. Phentermine has been approved by the US Food and Drug Administration (FDA) for weight management since 1959, but it has not been approved for long-term use (i.e., treatment lasting more than 12 weeks). This trial is designed to learn about the long-term effects of phentermine for up to 2 years because obesity is a chronic disease and expert guidelines recommend long-term use of anti-obesity medications as one treatment option.
The Long-term Effectiveness of the Anti-obesity medication Phentermine (LEAP) trial, a placebo-controlled, randomized trial, will be conducted at 5 clinical sites across the United States. All participants will be provided with an evidence-based online lifestyle intervention, and participants receiving 24 mg/day of phentermine vs. a placebo for up to 24 months will be compared in an intent-to-treat fashion. The co-primary outcomes of percent weight loss and change in systolic blood pressure at 24 months will be examined. Also, between group changes in drivers of energy balance, including resting metabolic rate, caloric intake, physical activity and dietary composition will be compared. To explore the effects of weight loss on cardiometabolic health, changes in heart rate, hemoglobin A1c, lipids, waist circumference, atherosclerotic cardiovascular disease (ASCVD) risk score, and novel ECG markers of cardiac strain will be compared. Overall adverse event and serious adverse event rate, including rates of incident cardiovascular disease or death, will be measured.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to active treatment in LEAP will be provided with phentermine hydrochloride 8 mg scored tablets. This formulation of the drug is commercially available and marketed as Lomaira TM.
Behavioral: Online Lifestyle Behavioral Therapy · Drug: Phentermine Hydrochloride 8 MG
Participants randomized to the control arm of LEAP will be provided with placebo tablets consisting of cellulose and corn starch and manufactured to have the same characteristics of the active drug, including size, shape, weight, and sensory perceptions.
Behavioral: Online Lifestyle Behavioral Therapy
Participants will receive access to the WW™ digital application for the duration of their participation. The WW™ digital application can be accessed using a smartphone, tablet or personal computer and includes functions such as food journaling, progress charts, lifestyle coaching , ability to manually enter exercise data or link with a fitness tracking device, incentives for behavior change, recipes, and local restaurant recommendations using GPS. Over the course of 12 clinic visits with an obesity provider, participants will be prescribed a dietary plan based on the WW™ app and will be asked to journal dietary intake.
At the randomization visit, participants will be started on 8 mg PO daily of phentermine or placebo, with a recommendation to take the medication in the morning. They will be provided with detailed instructions on how to increase their dose of study drug over the subsequent weeks. After one week, participants will increase to 16 mg daily. After the second week, participants will further increase their dose to 24 mg daily and at the 1-month in-person follow-up, participants who tolerate the 24 mg dose will be maintained on this as the maximum daily dose for a total of 24 months. For participants who do not tolerate an escalation in medication dose due to side effects, adverse events, and/or elevations in blood pressure and/or heart rate, the study clinician may adjust the dose and/or delay dose escalation. Study clinicians will work with participants to achieve and sustain the maximum dose tolerated.
Also known as: Lomaira
Change in body weight (%)
The primary outcome for efficacy will be percent weight loss at 24 months of follow-up, relative to body weight (kg) at randomization.
Time frame: Baseline to month 24
Change in Systolic Blood Pressure (mmHg)
The primary outcome to address phentermine's impact on a key cardiovascular disease risk factor, blood pressure, will be assessed at 24 months. Staff will measure BP using a standardized protocol with automated BP measurement devices (Omron HEM907XL) and following standard clinical practice guidelines for blood pressure measurement.
Time frame: Baseline to month 24
Change in resting energy expenditure (REE) / resting metabolic rate (RMR)
RMR will be measured via indirect calorimetry using the KORR ReeVue (KORR Medical Technologies, Salt Lake City, UT).
Time frame: Baseline to month 6; Baseline to month 24
Change in cardiac autonomic function
Change in cardiac autonomic function will be measured using heart rate variability with electrocardiogram (ECG). Heart rate variability (HRV) and resting heart rate (RHR) are noninvasive measures of cardiac autonomic function.
Time frame: Baseline to month 3; Baseline to month 6; Baseline to month 12; Baseline to month 24
Dependence on study drug (phentermine)
Dependence on study drug will be assessed using the Severity of Dependence Scale (SDS), a brief 5-item validated measure of psychological dependence that has been used for both illegal drugs of abuse and prescription drugs with concern for addiction potential. The score ranges from 0-15 with a higher score denoting a stronger dependence on the study drug.
Time frame: Month 24
Change in Systolic Blood Pressure (mmHg)
To address phentermine's impact on blood pressure over the course of the study, change in systolic blood pressure will be assessed at 6 months using a standardized measurement protocol with automated BP devices and following standard clinical practice guidelines for blood pressure measurement.
Time frame: Baseline to month 6; Baseline to month 12; Baseline to month 18
Incident cardiovascular disease or death
To address the impact of phentermine on cardiovascular disease and total mortality, participant diagnoses, hospitalizations, treatment, and deaths will be tracked via a combination of self-report and tracking within the electronic medical record.
Time frame: Month 1, Month 2, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
Change in body weight (%)
To assess the efficacy of phentermine at intervals throughout the study, percent weight loss at 6 and 12 months of follow-up relative to body weight (kg) at randomization will be measured.
Time frame: Baseline to month 6; Baseline to month 12
Change in self-reported physical activity levels
The International Physical Activity (IPAQ) short form is a 7-item index that asks respondents the number of days per week and the amount of time per day spent in vigorous- and moderate-intensity activities and walking, during the seven days prior to the visit. Different levels of physical activity are assigned metabolic equivalent (MET) scores based on the Compendium of Physical Activity and, using MET-minutes, can be converted to both continuous and categorical values
Time frame: Baseline to month 6; Baseline to month 12; Baseline to month 24
Plan to share: No
Ran from Jun 2022 to primary completion in Sep 2026, 51 months.
Of 190 non-industry phase 4 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's 51 months is above that.
Counting every sponsor, half of 210 studies reached it within 31 months; a quarter within 15 and three quarters within 51.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Dec 2026 → Sep 2026 and completion Dec 2026 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Phentermine
Wake Forest University Health Sciences →